Can linezolid be validly measured in endotracheal aspiration in critically ill patients? A proof-of-concept trial.
Bronchoalveolar lavage (BAL)
Critically ill patient
Endotracheal aspiration (ENTA)
Linezolid
Therapeutic drug monitoring
Journal
Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
28
02
2024
accepted:
03
05
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
epublish
Résumé
Therapeutic drug monitoring (TDM) of anti-infectives such as linezolid is routinely performed in blood of intensive care unit (ICU) patients to optimize target attainment. However, the concentration at the site of infection is considered more important for a successful therapy. Until now, bronchoalveolar lavage (BAL) is the gold standard to measure intrapulmonary concentrations of anti-infective agents. However, it is an invasive method and unsuitable for regular TDM. The aim of this proof-of-concept study was to investigate whether it is possible to reliably determine the intrapulmonary concentration of linezolid from endotracheal aspiration (ENTA). Intubated ICU patients receiving 600 mg intravenous linezolid twice daily were examined in steady state. First, preliminary experiments were performed in six patients to investigate which patients are suitable for linezolid measurement in ENTA. In a second step, trough and peak linezolid concentrations of plasma and ENTA were determined in nine suitable patients. Linezolid can validly be detected in ENTA with viscous texture and > 0.5 mL volume. The mean (SD) linezolid trough concentration was 2.02 (1.27) mg/L in plasma and 1.60 (1.36) mg/L in ENTA, resulting in a median lung penetration rate of 104%. The mean (SD) peak concentration in plasma and ENTA was 10.77 (5.93) and 4.74 (2.66) mg/L. Linezolid can validly be determined in ENTA with an adequate texture and volume. The penetration rate is comparable to already published BAL concentrations. This method might offer a simple and non-invasive method for TDM at the site of infection "lung". Due to promising results of the feasibility study, comparison of ENTA and BAL in the same patient should be investigated in a further trial.
Sections du résumé
BACKGROUND
BACKGROUND
Therapeutic drug monitoring (TDM) of anti-infectives such as linezolid is routinely performed in blood of intensive care unit (ICU) patients to optimize target attainment. However, the concentration at the site of infection is considered more important for a successful therapy. Until now, bronchoalveolar lavage (BAL) is the gold standard to measure intrapulmonary concentrations of anti-infective agents. However, it is an invasive method and unsuitable for regular TDM. The aim of this proof-of-concept study was to investigate whether it is possible to reliably determine the intrapulmonary concentration of linezolid from endotracheal aspiration (ENTA).
METHODS
METHODS
Intubated ICU patients receiving 600 mg intravenous linezolid twice daily were examined in steady state. First, preliminary experiments were performed in six patients to investigate which patients are suitable for linezolid measurement in ENTA. In a second step, trough and peak linezolid concentrations of plasma and ENTA were determined in nine suitable patients.
RESULTS
RESULTS
Linezolid can validly be detected in ENTA with viscous texture and > 0.5 mL volume. The mean (SD) linezolid trough concentration was 2.02 (1.27) mg/L in plasma and 1.60 (1.36) mg/L in ENTA, resulting in a median lung penetration rate of 104%. The mean (SD) peak concentration in plasma and ENTA was 10.77 (5.93) and 4.74 (2.66) mg/L.
CONCLUSIONS
CONCLUSIONS
Linezolid can validly be determined in ENTA with an adequate texture and volume. The penetration rate is comparable to already published BAL concentrations. This method might offer a simple and non-invasive method for TDM at the site of infection "lung". Due to promising results of the feasibility study, comparison of ENTA and BAL in the same patient should be investigated in a further trial.
Identifiants
pubmed: 38717627
doi: 10.1186/s40635-024-00630-x
pii: 10.1186/s40635-024-00630-x
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47Informations de copyright
© 2024. The Author(s).
Références
Vincent JL et al (2020) Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA 323:1478–1487. https://doi.org/10.1001/jama.2020.2717
doi: 10.1001/jama.2020.2717
pubmed: 32207816
pmcid: 7093816
Bauer M et al (2021) Mortality in sepsis and septic shock in Germany. Results of a systematic review and meta-analysis. Anaesthesist 70:673–680. https://doi.org/10.1007/s00101-021-00917-8
doi: 10.1007/s00101-021-00917-8
pubmed: 33559687
pmcid: 7871311
Abdul-Aziz MH et al (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med 46:1127–1153. https://doi.org/10.1007/s00134-020-06050-1
doi: 10.1007/s00134-020-06050-1
pubmed: 32383061
pmcid: 7223855
Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851; quiz 859. https://doi.org/10.1097/CCM.0b013e3181961bff
doi: 10.1097/CCM.0b013e3181961bff
pubmed: 19237886
Evans L et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181–1247. https://doi.org/10.1007/s00134-021-06506-y
doi: 10.1007/s00134-021-06506-y
pubmed: 34599691
pmcid: 8486643
Roberts JA et al (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498–509. https://doi.org/10.1016/S1473-3099(14)70036-2
doi: 10.1016/S1473-3099(14)70036-2
pubmed: 24768475
pmcid: 4181663
Lin B et al (2022) Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health 10:967311. https://doi.org/10.3389/fpubh.2022.967311
doi: 10.3389/fpubh.2022.967311
pubmed: 36033811
pmcid: 9399604
Bodmann KF, Grabein B, Kresken M (2020) S2k guideline “Calculated parenteral initial treatment of bacterial infections in adults—update 2018”, 2nd updated version: foreword. GMS Infect Dis 8:Doc20. https://doi.org/10.3205/id000064
doi: 10.3205/id000064
pubmed: 32373445
pmcid: 7186796
Zoller M et al (2014) Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care 18:R148. https://doi.org/10.1186/cc13984
doi: 10.1186/cc13984
pubmed: 25011656
pmcid: 4227093
Wu C et al (2022) Pharmacokinetic/pharmacodynamic parameters of linezolid in the epithelial lining fluid of patients with sepsis. J Clin Pharmacol. https://doi.org/10.1002/jcph.2031
doi: 10.1002/jcph.2031
pubmed: 36309848
pmcid: 10091977
Taubert M et al (2016) Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients. Antimicrob Agents Chemother 60:5254–5261. https://doi.org/10.1128/AAC.00356-16
doi: 10.1128/AAC.00356-16
pubmed: 27324768
pmcid: 4997846
Zoller M et al (2022) Serum linezolid concentrations are reduced in critically ill patients with pulmonary infections: a prospective observational study. J Crit Care 71:154100. https://doi.org/10.1016/j.jcrc.2022.154100
doi: 10.1016/j.jcrc.2022.154100
pubmed: 35780622
Roger C, Roberts JA, Muller L (2018) Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin Pharmacokinet 57:559–575. https://doi.org/10.1007/s40262-017-0601-x
doi: 10.1007/s40262-017-0601-x
pubmed: 29063519
De Pascale G et al (2015) Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Med 41:103–110. https://doi.org/10.1007/s00134-014-3550-y
doi: 10.1007/s00134-014-3550-y
pubmed: 25413377
American Association for Respiratory, C. AARC Clinical Practice Guidelines. Endotracheal suctioning of mechanically ventilated patients with artificial airways 2010. Respir Care. 2010; 55: 758–764.
Paal M et al (2021) Target site pharmacokinetics of meropenem: measurement in human explanted lung tissue by bronchoalveolar lavage, microdialysis and homogenized lung tissue. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01564-21
doi: 10.1128/AAC.01564-21
pubmed: 34871092
pmcid: 8597732
Paal M, Zoller M, Schuster C, Vogeser M, Schutze G (2018) Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS/MS method. J Pharm Biomed Anal 152:102–110. https://doi.org/10.1016/j.jpba.2018.01.031
doi: 10.1016/j.jpba.2018.01.031
pubmed: 29414000
Kato H et al (2021) Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist 24:98–105. https://doi.org/10.1016/j.jgar.2020.12.009
doi: 10.1016/j.jgar.2020.12.009
pubmed: 33401013
Boselli E et al (2012) Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother 67:1207–1210. https://doi.org/10.1093/jac/dks022
doi: 10.1093/jac/dks022
pubmed: 22351682
Baughman RP (2007) Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin Respir Crit Care Med 28:475–485. https://doi.org/10.1055/s-2007-991520
doi: 10.1055/s-2007-991520
pubmed: 17975775
Kiem S, Schentag JJ (2014) Interpretation of epithelial lining fluid concentrations of antibiotics against methicillin resistant Staphylococcus aureus. Infect Chemother 46:219–225. https://doi.org/10.3947/ic.2014.46.4.219
doi: 10.3947/ic.2014.46.4.219
pubmed: 25566401
pmcid: 4285007
Rodvold KA, Yoo L, George JM (2011) Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet 50:689–704. https://doi.org/10.2165/11592900-000000000-00000
doi: 10.2165/11592900-000000000-00000
pubmed: 21973267
Kiem S, Schentag JJ (2008) Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52:24–36. https://doi.org/10.1128/AAC.00133-06
doi: 10.1128/AAC.00133-06
pubmed: 17846133
Pea F, Cojutti PG, Baraldo M (2017) A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol 121:303–308. https://doi.org/10.1111/bcpt.12797
doi: 10.1111/bcpt.12797
pubmed: 28419737
Boselli E et al (2005) Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33:1529–1533. https://doi.org/10.1097/01.ccm.0000168206.59873.80
doi: 10.1097/01.ccm.0000168206.59873.80
pubmed: 16003058